TScan Therapeutics, Inc.

Item 1.02 Termination of a Material Definitive Agreement. On August 12, 2026, TScan Therapeutics, Inc. (the “Company”) received notice from Amgen Inc. (“Amgen”) of its election to terminate, in its entirety, the Research Collaboration and License Agreement, dated as of May 8, 2023, by and between the Company and Amgen (the “Collaboration Agreement”) pursuant to Amgen’s right under the Collaboration Agreement to terminate the agreement in its entirety upon 90 days’ prior written notice. Under the terms of the Collaboration Agreement, the termination will be effective 90 days following delivery of the notice, or November 10, 2026. No early termination penalty is payable by the Company in connection with the termination. Under the Collaboration Agreement, the Company and Amgen collaborated to use the Company’s proprietary target discovery platform to identify antigens recognized by T-cells in patients with Crohn’s disease. The Collaboration Agreement granted Amgen an exclusive, worldwide, sublicensable license to develop and commercialize product candidates created and developed during the collaboration. The Collaboration Agreement provided for a non-refundable, upfront payment of $30.0 million to the Company, which was received in 2023, success-based milestone payments of over $500 million in the aggregate, and tiered single-digit royalty payments on net sales of products developed from the collaboration. Upon receipt of written notice, the Company is obligated to use commercially reasonable efforts to promptly and efficiently wind down its activities under the then-current research plan. Upon the effective date of termination, the licenses granted under the Collaboration Agreement will terminate in accordance with its terms. Following termination, the Company does not expect to receive future milestone or royalty payments under the Collaboration Agreement unless Amgen, its affiliates or sublicensees continue to exploit product candidates, in which case applicable milestone and royalty obligations will survive in accordance with the terms of the Collaboration Agreement. The foregoing description of the Collaboration Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Collaboration Agreement, a copy of which is filed as Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, filed with the Securities and Exchange Commission on August 10, 2023, and incorporated by reference herein.